Aripiprazole

Research use only, not for human use.

Aripiprazole(Abilify) is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM.

Aripiprazole(Abilify) is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM.(In Vitro):Aripiprazole potently activates D2 receptor-mediated inhibition of cAMP accumulation.Aripiprazole shows a greater anti-inflammatory effect on TNF-α, IL-13, IL-17α and fractalkine.(In Vivo):Aripiprazole (0-3 mg/kg, IP, daily) shows some anxiolytic properties.

Aripiprazole potently activates D2 receptor-mediated inhibition of cAMP accumulation.Aripiprazole shows a greater anti-inflammatory effect on TNF-α, IL-13, IL-17α and fractalkine.

Aripiprazole (0-3 mg/kg, IP, daily) shows some anxiolytic properties. Animal Model:WAG/Rij rats (N = 6 per dose, 6 months, administration of a mixture of tiletamine/zolazepam)Dosage:0, 0.3, 1, 3 mg/kg Administration:IP, 1 mL/kg, every day at 5 p.m. until the end of the experiments Result:Showed some anxiolytic properties with the 1 mg/kg dose being the most active.

OPC 31 | OPC 14597

Endocrinology/Hormones

5-HT Receptor

5-HT1A

Neurological Disease

——

129722-12-9

448.39

C23H27Cl2N3O2

>98% (HPLC)

DMSO: 90 mg/mL (200.71 mM)

C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl

7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one

(-20℃)

With Ice Pack

≥ 2 years